Cells treated with the potent SRC inhibitor saracatinib and cells in the control group were subjected to transcriptome sequencing for the sake of understanding the downstream genes and pathways of SRC in KRAS-mutant NSCLC cells. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.